Introduction: Obesity and prostate cancer are related, but the causal relationship remains unknown. The aim of the study was to compare concentrations of leptin, adiponectin and chemerin in patients with prostate cancer and benign prostate hyperplasia and to examine associations of the adipokines with the grade of prostate cancer, interleukin-6 (IL-6), insulin resistance and anthropometric and metabolic variables.
Introduction
Different factors including age, low physical activity, dietary habits and family history favor the development of prostate cancer. Obesity or being overweight are recognized as a risk factors for prostate cancer [1] . Although the mechanisms underlying those associations are not fully recognized, it may be possible that insulin resistance, chronic inflammation and excess of adipose tissue or/and its dysfunction, known as adiposopathia, foster prostate cancerogenesis [2] . Adipokines produced by adipose tissue influence in metabolic processes and they mediate inflammation, cell proliferation and angiogenesis. The most abundant adipokines are leptin and adiponectin. In obesity, changes in their secretion may be associated with cancerogenesis [2] . Leptin serum levels are closely correlated with adipose tissue mass. The stimulating role of leptin in chronic inflammation, neoangiogenesis and tumorigenesis is established. The overexpression of leptin and its receptors has been well documented in numerous types of cancer [2, 3] . Another hormone which is secreted by adipose tissue is adiponectin. Various studies have been carried out to evaluate the relationships between adiponectin and cancerogenesis and most of them have reported that hypoadiponectinemia promotes tumor cell proliferation and influences mitogenic growth factors [2] . Chemerin is the next newly identified adipokine secreted by adipose tissue which may be associated with cancerogenesis. To our knowledge, there are no studies assessing circulating chemerin levels in patients with prostate cancer. Interleukin-6 (IL-6) is another cytokine produced by adipose tissue which serum levels are increased in obesity. This proinflammatory cytokine is involved in cancerogenesis by modulating cellular proliferation, invasion and angiogenesis. Previous studies regarding relationships between IL-6 and prostate cancer have reported essential role of this cytokine in development and progression of prostate cancer [4, 5] .
Large prospective studies [1] reveal that excess body adiposity promotes not only cancerogenesis but is also associated with increased risk of benign prostate hyperplasia. However, in molecular aspect, benign prostate hyperplasia and prostate cancer present two separate pathophysiological pathways and there are no direct relationships between those diseases. The common future of both diseases are hormonal dependence, slow progression and prostatic inflammation. However, it is not known whether links connecting obesity and prostate cancer and benign prostate hyperplasia are exactly the same. Therefore, the next aim of the study is to compare links connecting obesity and adipokines in group of patients with prostate cancer and benign prostate hyperplasia.
The specific goals of the study are: 1. Determining serum concentrations of adipokines:
leptin, adiponectin, chemerin and inflammatory cytokine IL-6 in patients with prostate cancer and with benign prostate hyperplasia.
Evaluating associations between adipokines and
histological types of prostate cancer. 3. Estimating the relationships between obesity, insulin resistance, inflammation and examined adipokines in both groups.
Material and methods
Our prospective study was conducted on 140 men treated at Urology Hospital UROVITA in Chorzow in 2014. All subjects who participated in the study gave the agreement in the written form. The study was approved by the local Ethical Review. Biopsies were performed by urologists with transrectal ultrasound. Depending on the results of histology findings, men were divided into two groups: I -prostatic cancer (n = 74) and II -with pathologic hyperplasia (n = 66), both groups were matched by BMI.
Exclusion criteria for both groups were: diabetes mellitus, heart, renal or liver failures and diagnosis of cancer other than prostate cancer. In all men anthropometric measurements were done: BMI was calculated as ratio of weight to square of height. Waist circumferences were measured. Blood samples were obtained in the morning time in fasting condition. Serum samples were stored frozen in -70 o C. In all participants metabolic profile was assessed (lipid profile and glucose concentrations) using enzymatic method. Serum leptin, adiponectin, chemerin and IL-6 concentrations were measured by ELISA methods using commercial assays. Leptin-to-adiponectin ratio was calculated as leptin in ng/mL divided by adiponectin in ug/mL. Serum PSA concentrations were assessed using immunochemical method (ECLIA). HOMA-I was calculated with formula: HOMA-I = fasting serum glucose concentration (mg/dL)/18.1 x fasting serum insulin concentration Serum concentrations of adipokines in men with prostate cancer and benign prostate hyperplasia Lucyna Siemińska et al.
(uIU/mL)/22.5 [6] . In the current study for diagnosis of insulin resistance we have used threshold value HOMA-I ≥ 2.5, as other researches [7] . Prostate cancer subjects were further subdivided according to BMI (values ≤ 25, ≤ 30, and > 30).
Considering histological differentiation prostate cancer patients were then divided into 3 subgroups according to the Gleason score: well differentiated (Gleason score ≤ 6), moderately differentiated subgroup (Gleason 7), and poorly differentiated (Gleason ≥ 8).
Statistical analysis were performed using STATIS-TICA 12.0, StatSoft Inc. Data were tested for normal distribution using W Shapiro-Wilk test. The results are presented as mean values with standard deviations and medians. Groups were compared by Student`s test or U Mann-Whitney test. Correlations between variables were estimated by calculating the correlation coefficient R by Pearson`s method or Spearman`s method. The prevalence of obesity and insulin resistance were compared using chi-squared test. Logistic regression analysis was used to estimated the odds ratios and 95%CI to evaluate the association between Gleason score (Gleason ≤ 6 vs. ≥ 7) and BMI ( < 25 vs. ≥ 25). All results were considered as statistically significant with p < 0.05.
Results
In the first part of the study we have analyzed the data from all 140 subjects according to the histological finding (group I -cancer, group II -benign hyperplasia). The characteristics of men are summarized in Table I .
Statistical analysis showed that mean age of cancer group was higher than in hyperplasia group (67.13 ± 8.48 versus 61.51 ± 10.30). The mean BMI in group I was 27.90 ± 3.27 and was similar to group II (27.25 ± 3.97). There were no differences between groups in waist circumference, HOMA-I, serum levels of total cholesterol, glucose, triglycerides, adiponectin, leptin and chemerin. However, as shown in Table I , the concentrations of PSA, IL-6 and leptin-to-adiponectin ratio were significantly higher in cancer group compared with benign hyperplasia group.
The prevalence of subjects with BMI > 30 did not differ between group I and II (24.32%, n = 18 vs. 22.73%, n = 15, respectively). The proportions of overweight men, defined as 25-30 kg/m 2 , were also similar (55.45%, n = 41 in cancer group, 48.48%, n = 32 in benign prostate hyperplasia group). The proportions of normal BMI men (BMI < 25 kg/m 2 ), were similar (20.27%, n = 15 in group I, 28.79%, n = 19 in group II). The prevalence of insulin resistance was similar in both groups -it was recognized in 58%, n = 43 prostate cancer patients and in 54.4%, n = 36 benign prostate hyperplasia patients. Table II shows the clinical and biochemical characteristics of patients by prostate cancer severity. In the poorly differentiated cancer subgroup, subjects were older, had higher PSA, leptin, chemerin, IL-6 and triglycerides concentrations and higher leptin-to-adiponectin ratio. 
PRACE ORYGINALNE
Then logistic regression analysis was performed to calculate odds ratio (OR) for the presence of moderately and poorly differentiated PC (Gleason score ≥ 7). Cases with BMI ≥ 25 tended to have higher Gleason score. Odds ratio for subjects with BMI ≥ 25 was 3.11 (95% confidence interval CI 1.01-9.52).
In the next step of the study we assessed the correlations of serum adipokines with analyzed variables in all participants, as well as in both groups separately (Table III) .
In the all men serum adiponectin was significantly correlated with HOMA-I, BMI, glucose, triglycerides, cHDL (Table III) . There were strong significant correlations between leptin and BMI, HOMA-I, waist, glucose, triglycerides and cHDL. Among all the participants we observed associations between chemerin and waist as well as triglycerides. In prostate cancer patients chemerin correlated also with IL-6 (R = 0.17, p < 0.05) and leptin (R = 0.22, p < 0.01) - Figure I . We also measured a significant positive correlation between serum chemerin and Gleason score (R = 0.32, p < 0.01), as well as between serum leptin and Gleason score (R = 0.20, p < 0.05). There was a positive correlation between adiponectin and PSA levels in all men (R = 0.32, P < 0.001), as well as in cancer group (R = 0.27, p < 0.01).
Discussion
Obesity is associated with increased risk of various cancers including: breast, renal, colon, corpus uteri and prostate [2, 8] . It is estimated that in 2012 about 3.6 % of all new cases of cancer in adults can be attributed to high BMI [9] . There is a gradual increase of prostate cancer incidence, especially in developed countries, according to increasingly Western eating abits. Accumulating evidences suggest that visceral obesity is associated with higher risk of progression and recurrence of prostate cancer [10, 11] . However, several studies have given contradictory results and have failed to confirm the associations between greater BMI and worse prostate cancer prognosis [12, 13] . Our results are concordant with previous studies which determined that obesity is associated with higher aggressiveness. In our study the association between BMI and prostate cancer upgrading based on Gleason sum has been revealed. We have found that overweight and obese men with prostate cancer were three times more likely to have Gleason score ≥ 7 than those with normal BMI. Of note, this study was not conducted among random population because the studied group included men from Silesian population, which is characterized by growing percentage of obesity during the last time [14] . It might significantly affect the obtained results. Obesity may influence prostate cancer development and aggressiveness in various ways. One of the mechanisms linking obesity and cancerogenesis may be adipose tissue dysfunction with altered adipokines secretion and persistent inflammation [15] . Another potential factor to explain the link between obesity and cancer is hyperinsulinemia and increased IGF-I response to GH [16] . In this study we have focused on the serum concentrations of adipokines which concentrations are related to the adiposity: leptin, adiponectin and chemerin. Indeed, in our study we have observed correlations between adipokines and BMI, waist circumferences and different parameters of metabolic profile such as glucose, triglycerides and cHDL. 
PRACE ORYGINALNE
Leptin concentrations are increased in obese patients and it is well documented that this hormone stimulates tumor cells growth and invasion. There is a growing evidence of its role in development of colorectal, hepatocellular, breast and thyroid cancer [17] . Observation that leptin receptors have high expression in the prostate proves leptin role in pathophysiology processes [18] . Different studies have evaluated a role of leptin in the pathogenesis of prostate cancer but the results are contradictory. Some authors reported that hyperleptinemia is associated with increased risk for prostate cancer [19, 20] , but recently published data about this subject are inconsistent [21, 22] . In this study we have found that serum leptin levels were similar in prostate cancer and benign hyperplasia patients. However, subjects with poorly differentiated cancer had higher leptin levels than patients with well differentiated cancer. Our results are in agreement with the previously published data [23] . This association could be explained considering that hyperleptynemia promotes neoangiogenesis and prostate cancer cells proliferation. In our study leptin were correlated with IL-6 and with insulin resistance in both groups, however only in the cancer group we have demonstrated relationships between leptin and chemerin and between IL-6 and chemerin. It is possible that leptin interacts with other hormones and cytokines and the crosstalking between them fosters cancerogenesis and invasion.
In this study we have observed that prostate cancer men exhibit elevated serum IL-6 concentrations when compared with benign prostate hyperplasia men. Our finding are in agreement with those obtained by other researchers [24, 25] . Increased levels of this inflammatory cytokine modulate the expression of genes responsible for cell proliferation and angiogenesis via the JAK-STAT signaling pathway. Shariat et al described that increased inflammatory cytokines concentrations might be involved in prostate cancer aggressiveness [25] . In this study we have observed higher IL-6 levels in poorly differentiated cancer subgroup than in well differentiated prostate cancer subgroup and we have demonstrated relationships between IL-6 and chemerin which also was connected with prostate cancer aggressiveness. It is possible that chronic inflammation which is associated with disturbed adipokine secretion and signaling, fosters prostate cancer development and growth.
Reduced serum adiponectin has been seen in a number of different cancers such as oesophageal, gastric, pancreatic, colorectal, hepatic, breast, endometrial cancer, lung and renal [26] . In our study we didn't observe the differences in serum adiponectin between prostate cancer and benign prostate hyperplasia and we didn`t demonstrate correlations with Gleason score, which was postulated by some researchers [27] [28] [29] .
Results of studies examined relationships between serum adiponectin and prostate cancer are contradictory. AdipoR1 and AdipoR2 have been identified on both benign and malignant human prostate cells [30] . However, the epithelium of malignant prostatic glands showed an enhanced adiponectin expression in comparison with benign hyperplasia [30] . In vitro studies have demonstrated that adiponectin exerts effects on prostate cancer cells by modulating AMPK and PI3 kinase/Akt pathways [31] . Series studies have reported that patients with prostate cancer exhibited decreased serum adiponectin concentrations as compared in men with benign prostate cancer or in healthy controls [27] [28] [29] . Moreover, adiponectin was significantly and inversely connected with prostate stage or Gleason score [28] . Some authors described inverse associations only in overweight or obese men, but not in normal weight or in all men [32] . However, few studies are consistent with our observations and have excluded the potential relations between low adiponectin concentration and prostate cancer risk [22, 30, 33] . In this study, adiponectin concentrations have reflected mainly metabolic status and have correlated with HOMA-I, cHDL and triglycerides levels in both cancer and benign hyperplasia groups. Furthermore, in cancer group adiponectin was connected with BMI and waist circumference. Besides, in all men and in the cancer group we have found significant correlations between adiponectin and PSA concentrations. Our results are in agreement with results of the study by Ikeda et al. who also have found the significant associations between adiponectin and PSA in almost 3000 Japanese men [34] . However, nature of those dependencies is unknown and there is a need for further clinical and experimental studies to resolve the nature of those relationships.
Although we didn`t detect significant differences in adiponectin or leptin levels, we have manifested significantly larger leptin-to-adiponectin ratio in cancer men in comparison to benign hyperplasia group. To the best of our knowledge this is the first study in which higher ratio was detected in prostate cancer men, regardless of anthropometric parameters. Although Tewari et al. have observed higher proportion between high leptin and low adiponectin in prostate cancer group, they have obtained results which were depended on different nutritional status of studied groups [35] . In the poorly differentiated cancer subgroup, subjects had higher leptin-to-adiponectin ratio. It is assumed that leptinto-adiponectin index represents more precise marker of adipose tissue dysfunction [36] . It suggests that not isolated adipokines are critical in the development of prostate cancer but imbalance between leptin and adiponectin may be a crucial moment in cancerogenesis and aggressiveness.
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Chemerin is an adipokine expressed and secreted predominantly by adipocytes which is associated with obesity and metabolic syndrome. This adipokine is involved in metabolism and immune reactions. Recently, the potential role of chemerin in cancerogenesis was described [37, 38] . Higher chemerin levels were observed in non-small cell lung cancer patients compared with healthy controls and were associated with advanced TNM stage [37] . Elevated serum levels of chemerin were also determined in gastric cancer and colorectal cancer patients [38] . To our knowledge, the relationship between chemerin and prostate cancer has not been investigated previously. Therefore, we assessed chemerin levels in prostate cancer men and compared with patients with diagnosed benign prostatic hyperplasia but we didn`t find the differences between groups. However, after subdividing prostate cancer group considering the Gleason score, it was found that chemerin concentrations has grown simultaneously with prostate cancer severity. Further studies are needed to explain the mechanism underlying this increase. It should be noted that in the cancer group the chemerin concentrations positively correlated with leptin, IL-6 levels and leptin-to-adiponectin ratio. In addition, chemerin levels were affected by nutritional status, as chemerin concentrations were proportional to BMI, waist circumferences and triglycerides levels. It is possible that cluster of adipokines and cytokines perturbation may contribute to cancerogenesis and aggressiveness of prostate cancer.
In summary, leptin-to-adiponectin ratio and IL-6 were elevated in men with prostate cancer. Leptin, chemerin, IL-6 and leptin-to-adiponectin ratio were associated with Gleason score but the relationships were dependent on each other. Overweight and obese men with prostate cancer were more likely to have moderately differentiated or poorly differentiated cancer than those with normal BMI.
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